Anticorps thérapeutiques et maladies infectieuses

Christine Klinguer-Hamour; Véronique Caussanel; Alain Beck

doi:10.1051/medsci/200925121116

Accueil

Tous les numéros

Volume 25 / Numéro 12 (Décembre 2009)

Med Sci (Paris), 25 12 (2009) 1116-1120

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 25, Numéro 12, Décembre 2009 Anticorps monoclonaux en thérapeutique


Page(s)		1116 - 1120
Section		II - La réalité clinique
DOI		https://doi.org/10.1051/medsci/200925121116
Publié en ligne		15 décembre 2009

Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25 : 1421–34. [Google Scholar]
Ledford H. Monoclonal antibodies come of age. Nature 2008; 455 : 437. [Google Scholar]
Dau B, Holodniy M. Novel targets for antiretroviral therapy: clinical progress to date. Drugs 2009; 69 : 31–50. [Google Scholar]
Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11 : 615–22. [Google Scholar]
Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449 : 101–4. [Google Scholar]
Karlsson Hedestam GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008; 6 : 143–55. [Google Scholar]
Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov 2006; 5 : 191–5. [Google Scholar]
Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4 : e178. [Google Scholar]
Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455 : 532–6. [Google Scholar]
Mansbach J, Kunz S, Acholonu U, et al. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. Pediatr Emerg Care 2007; 23 : 362–7. [Google Scholar]
Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368 : 652–5. [Google Scholar]
De Kruif J, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007; 58 : 359–68. [Google Scholar]
Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 2008; 14 : 1357–62. [Google Scholar]
Reichert JM. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007; 21 : 1–7. [Google Scholar]
Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11 : 522–30. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25 : 1421–34. [Google Scholar]

[2] Ledford H. Monoclonal antibodies come of age. Nature 2008; 455 : 437. [Google Scholar]

[3] Dau B, Holodniy M. Novel targets for antiretroviral therapy: clinical progress to date. Drugs 2009; 69 : 31–50. [Google Scholar]

[4] Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11 : 615–22. [Google Scholar]

[5] Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449 : 101–4. [Google Scholar]

[6] Karlsson Hedestam GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008; 6 : 143–55. [Google Scholar]

[7] Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov 2006; 5 : 191–5. [Google Scholar]

[8] Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4 : e178. [Google Scholar]

[9] Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455 : 532–6. [Google Scholar]

[10] Mansbach J, Kunz S, Acholonu U, et al. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. Pediatr Emerg Care 2007; 23 : 362–7. [Google Scholar]

[11] Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368 : 652–5. [Google Scholar]

[12] De Kruif J, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007; 58 : 359–68. [Google Scholar]

[13] Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 2008; 14 : 1357–62. [Google Scholar]

[14] Reichert JM. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007; 21 : 1–7. [Google Scholar]

[15] Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11 : 522–30. [Google Scholar]